Experimental Autoimmunity to Rat Male Accessory Glands (MAG): Circulating Antibodies, Immunoglobulins Bound to Target Glands, and Immunoglobulins‐Secreting Cells

Depiante-Depaoli, M; Pacheco-Rupil, B

doi:10.1111/j.1600-0897.1985.tb00260.x

Cited by 15 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further support for the autoimmune nature of CP/CPPS is provided by EAP models in rodents (45)(46)(47). They have been extensively characterized, demonstrating that immunization of rats or mice with prostate gland extracts can induce T cell and Ab responses to prostate Ags, associated with histological evidence of prostate inflammation.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Experimental Autoimmune Prostatitis in Nonobese Diabetic Mice by the Vitamin D Receptor Agonist Elocalcitol

Penna

Amuchastegui

Cossetti

et al. 2006

The Journal of Immunology

116

View full text Add to dashboard Cite

On the basis of on the marked inhibitory activity of the vitamin D receptor agonist Elocalcitol on basal and growth factor-induced proliferation of human prostate cells and on its potent anti-inflammatory properties, we have tested its capacity to treat experimental autoimmune prostatitis (EAP) induced by injection of prostate homogenate-CFA in nonobese diabetic (NOD) mice. Administration of Elocalcitol, at normocalcemic doses, for 2 wk in already established EAP significantly inhibits the intraprostatic cell infiltrate, leading to a profound reduction in the number of CD4+ and CD8+ T cells, B cells, macrophages, dendritic cells, and I-Ag7-positive cells. Immunohistological analysis demonstrates reduced cell proliferation and increased apoptosis of resident and infiltrating cells. Significantly decreased production of the proinflammatory cytokines IFN-γ and IL-17 is observed in prostate-draining lymph node T cells from Elocalcitol-treated NOD mice stimulated by TCR ligation. In addition, Elocalcitol treatment reduces IFN-γ production by prostate-infiltrating CD4+ T cells and draining lymph node T cells specific for an immunodominant peptide naturally processed from prostate steroid-binding protein, a prostate-specific autoantigen. Finally, CD4+ splenic T cells from Elocalcitol-treated NOD mice show decreased ability, upon adoptive transfer into NOD.SCID recipients, to induce autoimmune prostatitis, paralleled by a reduced capacity to produce IFN-γ in response to prostate steroid-binding protein. The results indicate that Elocalcitol is able to interfere with key pathogenic events in already established EAP in the NOD mouse. These data show a novel indication for vitamin D receptor agonists and indicate that treatment with Elocalcitol may inhibit the intraprostatic inflammatory response in chronic prostatitis/chronic pelvic pain syndrome patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Experimental Autoimmune Prostatitis in Nonobese Diabetic Mice by the Vitamin D Receptor Agonist Elocalcitol

Penna

Amuchastegui

Cossetti

et al. 2006

The Journal of Immunology

116

View full text Add to dashboard Cite

show abstract

“…CPPS rat models are currently widely used to study the mechanism between pain and inflammation in human prostatitis (25). EAP rat modeling refers to subcutaneously injecting homologous rat prostate antigens into SD rats to induce prostatitis and paraesthesia of pelvis.…”

Section: Resultsmentioning

confidence: 99%

“…Chronic prostatitis is a disease caused by a number of factors (25) that may lead to discomfort in the groin area, pelvic pain, irritable urination and sexual dysfunction (26). Its histological characterization is the infiltration of multinucleate and mononuclear cells into interstitial connective tissues (27).…”

Section: Discussionmentioning

confidence: 99%

The mediation of interleukin-17 and chemokine ligand 2 in pelvic pain of experimental autoimmune prostatitis

Liu

Fan

Zheng

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The present study aimed to determine the expression and mediation of interleukin-17 (IL-17) and chemokine ligand 2 (CCL2) in a rat model with experimental autoimmune prostatitis (EAP). A total of 44 Sprague Dawley (SD) rats were used in the present study. Of these, a total of 20 two-month-old SD rats were randomly divided into a normal control (n=10) and a model group (EAP group, n=10). The remaining 24 two-month old SD rats were treated in the same way as EAP rats and subsequently randomly divided into a tacrolimus group (n=8), a celecoxib group (n=8) and a normal saline (NS) control group (n=8). Rats in the EAP and normal control groups underwent the Von Frey filaments behavioral test; rats in the tacrolimus, celecoxib and normal saline groups received a pain test following intervention treatment. Prostate tissues of SD rats in each group were harvested for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis to observe the expression of IL-17 and CCL2. In the pain-reaction test, the occurrence of abnormal pain in the EAP group was significantly higher compared with the control group (P<0.001). The celecoxib group experienced a significant decrease in pain at day 10 compared with the NS group (P<0.01), while the decrease in pain experienced by the tacrolimus group was only significant at day 30 (P<0.001) and the pain experienced by the NS group decreased slightly over this same period. Results of RT-qPCR and western blot analysis indicated that, compared with the control group, the expression of IL-17 and CCL2 in the prostate tissue of EAP rats was significantly upregulated 50 days following modeling (P<0.05). On day 30 following intervention, the expression of IL-17 and CCL2 in the prostate of rats in the tacrolimus and celecoxib groups was significantly downregulated compared with the NS group (P<0.05). Therefore, the results of the current study demonstrate that IL-17 and CCL2 serve a vital role in the morbidity of the experimental autoimmune prostatitis and may also have a mediation effect on pelvic pain associated with chronic prostatitis.

show abstract

“…In addition, prostate protein was extracted from another 18 adult male rats. The EAP rat model was established in the EAP model group and celecoxib group following a modified classical modeling method of two-step immunization ( 9 ). Briefly, prostates excised from Wistar rats were homogenized in 0.5% Triton X-100 (Sigma, Aldrich, United States) with an electric homogenizer (HZYBDJ, Hangzhou, China).…”

Section: Methodsmentioning

confidence: 99%

“…Bacterial infection, urine reflux, autoimmune response, neuroendocrine disorder, and anxiety-related factors have been reported to associate with CP/CPPS ( 7 ). Based on the theory that immunopathogenic mechanisms ( 8 ) are involved, an experimental autoimmune prostatitis (EAP) animal model was established in rodents by generating an autoimmune response to various antigens, including an homogenate of male accessory glands (MAG) ( 9 ) or prostate ( 10 ), human prostate acid phosphatase (PAP) ( 11 ), prostate steroid binding protein (PSPB) ( 12 ), and peptide T2 ( 13 ). EAP rat is characterized by a prostate-specific cellular and humoral immune response with active inflammatory monocyte infiltration ( 14 ).…”

Section: Introductionmentioning

confidence: 99%

Influence of Experimental Autoimmune Prostatitis on Sexual Function and the Anti-inflammatory Efficacy of Celecoxib in a Rat Model

Zhang

Zhou

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Experimental autoimmune prostatitis (EAP) is a well-established model induced by an autoimmune response to prostate antigen. The symptomatic, pathological, and immunological characteristics of EAP animals are highly consistent with human chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), which makes EAP an ideal model for this disease. Here, we investigate the influence of EAP on male rat sexual function and the efficacy of anti-inflammatory therapy with celecoxib. EAP rat models were established using male Wistar rats. Rats were randomly assigned to a normal control group, an EAP model group, or an EAP model with celecoxib treatment group (celecoxib group). Behavioral changes, sexual behavioral changes, and erectile function were estimated using an open-field test, a sucrose consumption test, mating experiments, and by intracavernous pressure/mean arterial pressure ratio (ICP/MAP). Histological changes in the prostate were observed by HE staining, and the serum inflammatory factors IL-1β and TNF-α levels were measured by enzyme-linked immunosorbent assay. In addition, serotonin (5-hydroxytryptamine, 5-HT), 5-HT 1A receptor, 5-HT 2C receptor, and serotonin transporter (SERT) expression levels in the hippocampus and spinal cord (T13-L1, L5-S2) were examined by immunohistochemistry and western blot analysis. Results showed that EAP rats exhibited characteristics of depression, decreased sexual drive, premature ejaculation, and increased threshold of penile erection. Moreover, all these changes were effectively alleviated by celecoxib. Significant increases in prostatic interstitial infiltration by inflammatory cells and in serum IL-1β and TNF-α levels were observed in EAP rats, and these were partially reduced by celecoxib. Additionally, the expression pattern of serotonin system regulators in the hippocampus and spinal cord were altered in EAP model rats, including a decrease in 5-HT levels and an increase in 5-HT 1A receptor levels. In conclusion, autoimmune prostatitis impaired rat sexual function, and this was effectively prevented by anti-inflammatory therapy with celecoxib. Moreover, a serotonin system disorder in the central nervous system was likely mediated via inflammation in EAP rats.

show abstract

Experimental Autoimmunity to Rat Male Accessory Glands (MAG): Circulating Antibodies, Immunoglobulins Bound to Target Glands, and Immunoglobulins‐Secreting Cells

Cited by 15 publications

References 17 publications

Treatment of Experimental Autoimmune Prostatitis in Nonobese Diabetic Mice by the Vitamin D Receptor Agonist Elocalcitol

Treatment of Experimental Autoimmune Prostatitis in Nonobese Diabetic Mice by the Vitamin D Receptor Agonist Elocalcitol

The mediation of interleukin-17 and chemokine ligand 2 in pelvic pain of experimental autoimmune prostatitis

Influence of Experimental Autoimmune Prostatitis on Sexual Function and the Anti-inflammatory Efficacy of Celecoxib in a Rat Model

Contact Info

Product

Resources

About